Humana · Hizentra CIDP · US health-plan appeal rights

Hizentra CIDP denied as duplicate or overlapping therapy by Humana?

Q: How long do I have to appeal a Humana Hizentra CIDP denial?

Internal appeal window: Typically 180 days from the denial date. External review window: Typically 60–120 days after the final internal denial. The clock starts from the date on the denial letter.

If two medications appear duplicative on paper but serve different clinical purposes (e.g., short-acting vs long-acting), the appeal needs to spell out the clinical rationale for both.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-05-09

Policy data current as of 2026-04-26

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.

Internal appeal window

Typically 180 days from the denial date

External review window

Typically 60–120 days after the final internal denial

What Humana typically requires

Humana's specific coverage criteria for hizentra cidp are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

Source policy: Humana Hizentra (Immune Globulin Subcutaneous) for CIDP Maintenance

The Humana angle on Hizentra CIDP

## Why Humana May Deny Hizentra for CIDP as "Duplicate Therapy"

Humana may issue a duplicate-therapy denial for Hizentra (subcutaneous immune globulin) in chronic inflammatory demyelinating polyneuropathy (CIDP) when its records show that the member is already receiving another form of immune globulin therapy — most commonly intravenous immunoglobulin (IVIG). The plan's logic is that both products deliver the same active substance (immunoglobulin) and that paying for both simultaneously is clinically redundant.

This denial is frequently incorrect or premature. A prescriber may be transitioning a stable patient from IVIG to subcutaneous IG precisely to eliminate infusion-center visits, reduce systemic side effects, and improve adherence — a transition recognized in clinical practice as a deliberate therapeutic substitution, not duplication. The appeal should make this rationale explicit and document that the transition is underway.

## Federal Appeal Rights

ACA §2719 / external review: After Humana's internal appeal is exhausted, you may request independent external review. The standard deadline is approximately four months from the initial denial; your denial notice will state the exact date. Expedited external review (often 72 hours) is available when the clinical situation is urgent.
ERISA §503: If your coverage is through an employer self-funded plan, Humana must provide the specific duplicate-therapy criterion applied and a full-and-fair review of the appeal.

## What to Gather

1. Prescriber transition plan — a signed letter explaining the clinical rationale for switching from IVIG to Hizentra, including the anticipated overlap period and when the prior therapy will be discontinued. 2. Diagnosis confirmation — neurology notes or EMG/nerve conduction study results establishing the CIDP diagnosis and current disease activity. 3. Prior-therapy outcomes — documentation of the IVIG course: response, tolerability, and clinical basis for transitioning. 4. Treatment timeline — a clear date-by-date schedule showing the overlap is temporary and intentional, not ongoing co-administration. 5. Humana's duplicate-therapy policy — request a copy and address each stated criterion explicitly.

## Criteria-Mapping Structure

| Humana Criterion | Chart or Prescriber Evidence | |---|---| | Each stated duplicate-therapy requirement | Date, note, or documented rationale |

Next steps

Find the date on the denial letter — your appeal window starts there.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the insurer's claim file in writing — they must provide it.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other Humana appeals

Other denial reasons for Humana Hizentra CIDP

denied as not medically necessary denied for failing step therapy denied as non-formulary denied for missing prior authorization denied as experimental or investigational

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-05-09. Editorial standards: denialhelp.com/authors.